 Supportive measures and dose modifications: A subject who experiences a treatment-related grade 3 or higher adverse event AE must be withdrawn from protocol treatment and should proceed to surgery and undergo an EoS visit. In the case of a grade 1-2 treatment-related AE, the Investigator should contact the Medical Monitor if a dose reduction or treatment hold is required. 